FDA approval summary: TAS-102

Clinical Cancer Research

Volumn 23, Issue 12, 2017, Pages 2924-2927

  Marcus, Leigh ^a   Lemery, Steven J ^a   Khasar, Sachia ^a   Wearne, Emily ^a   Helms, Whitney S ^a   Yuan, Weishi ^a   He, Kun ^a   Cao, Xianhua ^a   Yu, Jingyu ^a   Zhao, Hong ^a   Wang, Yaning ^a   Stephens, Olen ^a   Englund, Erika ^a   Agarwal, Rajiv ^a   Keegan, Patricia ^a   Pazdur, Richard ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROPYRIMIDINE; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; PLACEBO; TIPIRACIL PLUS TRIFLURIDINE; TRIFLURIDINE; URACIL;

ABDOMINAL PAIN; ADULT; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASIAN; ASTHENIA; CANCER SURVIVAL; CAUCASIAN; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DRUG APPROVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; INFECTION; INTERSTITIAL LUNG DISEASE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MIDDLE AGED; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; URINARY TRACT INFECTION; VOMITING; ADVERSE DRUG REACTION; AGED; ANALOGS AND DERIVATIVES; CLASSIFICATION; CLINICAL TRIAL; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; DRUG COMBINATION; DRUG EFFECTS; DRUG RESISTANCE; FOOD AND DRUG ADMINISTRATION; MULTICENTER STUDY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; UNITED STATES;

ADULT; AGED; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG APPROVAL; DRUG COMBINATIONS; DRUG RESISTANCE, NEOPLASM; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; TRIFLURIDINE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; URACIL;

EID: 85020776280     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-2157     Document Type: Article

References (11)

1. U.S. Food and Drug Administration. USPI trifluridine and tipiracil (issue date September 2015) [PDF on the Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2015 [cited 2016 Dec 14]. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/label/2015/207981s000lbl.pdf.
2. Drugs@FDA [database on the Internet]. Chemistry review(s). Silver Spring (MD): U.S. Food and Drug Administration; 2015 [cited 2016 Feb 9]. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2015/207981Orig1s000ChemR.pdf.
3. Fukushima M, Suzuki N, Emura T, Yano S, Kazuno H, Tada Y, et al. Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2′-deoxyribonucleosides. Biochem Pharmacol 2000;59:1227-36.
4. Lenz HJ, Stintzing S, Loupakis S. TAS-102, a novel antitumor agent: a review of the mechanism of action. Cancer Treat Rev 2015;41:777-83.
5. Tsuchiya H, Kuwata K, Nagayama S, Yamashita K, Kamiya H, Harashima H. Pharmacokinetic modeling of species-dependent enhanced bioavailability of trifluorothymidine by thymidine phosphorylase inhibitor. Drug Metab Pharmacokinet 2004;19:206-15.
6. Drugs@FDA [database on the Internet]. Pharmacology review(s). Silver Spring (MD): U.S. Food and Drug Administration; 2015 [cited 2016 Dec 14]. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2015/207981Orig1s000PharmR.pdf.
7. Drugs@FDA [database on the Internet]. Clinical pharmacology and biopharmaceutics review(s). Silver Spring (MD): U.S. Food and Drug Administration; 2015 [cited 2016 Dec 19]. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2015/207981Orig1s000ClinPharmR.pdf.
8. Yoshino T, Mizunuma N, Yamazaki K, Nishina T, Komatsu Y, Baba H, et al. TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol 2012;13:993-1001.
9. Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 2015;372:1909-19.
10. U.S. Food and Drug Administration. Guidance for industry: codevelopment of two or more new investigational drugs for use in combination [PDF on the Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2013 [cited 2016 Dec 19]. Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm236669.pdf.
11. U.S. Food and Drug Administration. Guidance for industry: providing clinical evidence of effectiveness for human drug and biological products [PDF on the Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 1998 [cited 2016 Dec 19]. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072008.pdf.